Search research articles
Contact Us
Filters
Showing results (131-140 of 169) with videos related to
Page
of 17
Sort By:
Blood
|
July 26, 2019
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
Constantine S Tam, Judith Trotman, Stephen Opat, et al.
Eclinicalmedicine
|
January 9, 2023
The iR<sup>2</sup> regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 study
Radhakrishnan Ramchandren, Peter Johnson, Nilanjan Ghosh, et al.
Advances in Radiation Oncology
|
December 11, 2025
Reduced-Dose Hypofractionated Radiation Therapy (3 Gy × 3 Fractions) for Indolent Non-Hodgkin's lymphoma (POSEIDON): A Multisite Phase 2 Randomized Trial Protocol
Omran Saifi, Scott C Lester, William G Rule, et al.
Nature Communications
|
June 17, 2015
CD24 tracks divergent pluripotent states in mouse and human cells
Nika Shakiba, Carl A White, Yonatan Y Lipsitz, et al.
American Journal of Hematology
|
December 24, 2019
Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study
Martin Dreyling, Armando Santoro, Luigina Mollica, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 11, 2020
BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis
Elizabeth Punnoose, Franklin V Peale, Edith Szafer-Glusman, et al.
International Journal of Radiation Oncology, Biology, Physics
|
December 23, 2022
Don't Put the CART Before the Horse: The Role of Radiation Therapy in Peri-CAR T-cell Therapy for Aggressive B-cell Non-Hodgkin Lymphoma
Omran Saifi, William G Breen, Scott C Lester, et al.
Haematologica
|
June 15, 2023
Consolidative radiotherapy for residual fluorodeoxyglucose activity on day +30 post CAR T-cell therapy in non-Hodgkin lymphoma
Omran Saifi, William G Breen, Scott C Lester, et al.
Blood Advances
|
October 11, 2022
Barriers to enrollment in clinical trials of patients with aggressive B-cell NHL that progressed after CAR T-cell therapy
Evandro D Bezerra, Madiha Iqbal, Javier Munoz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 6, 2022
Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study
Michael Wang, Javier Munoz, Andre Goy, et al.
Page
of 17
Search research articles
Search
Showing results (131-140 of 169) with videos related to
Sort By:
Page
of 17
Blood
|
July 26, 2019
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
Constantine S Tam, Judith Trotman, Stephen Opat, et al.
Eclinicalmedicine
|
January 9, 2023
The iR<sup>2</sup> regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 study
Radhakrishnan Ramchandren, Peter Johnson, Nilanjan Ghosh, et al.
Advances in Radiation Oncology
|
December 11, 2025
Reduced-Dose Hypofractionated Radiation Therapy (3 Gy × 3 Fractions) for Indolent Non-Hodgkin's lymphoma (POSEIDON): A Multisite Phase 2 Randomized Trial Protocol
Omran Saifi, Scott C Lester, William G Rule, et al.
Nature Communications
|
June 17, 2015
CD24 tracks divergent pluripotent states in mouse and human cells
Nika Shakiba, Carl A White, Yonatan Y Lipsitz, et al.
American Journal of Hematology
|
December 24, 2019
Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study
Martin Dreyling, Armando Santoro, Luigina Mollica, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 11, 2020
BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis
Elizabeth Punnoose, Franklin V Peale, Edith Szafer-Glusman, et al.
International Journal of Radiation Oncology, Biology, Physics
|
December 23, 2022
Don't Put the CART Before the Horse: The Role of Radiation Therapy in Peri-CAR T-cell Therapy for Aggressive B-cell Non-Hodgkin Lymphoma
Omran Saifi, William G Breen, Scott C Lester, et al.
Haematologica
|
June 15, 2023
Consolidative radiotherapy for residual fluorodeoxyglucose activity on day +30 post CAR T-cell therapy in non-Hodgkin lymphoma
Omran Saifi, William G Breen, Scott C Lester, et al.
Blood Advances
|
October 11, 2022
Barriers to enrollment in clinical trials of patients with aggressive B-cell NHL that progressed after CAR T-cell therapy
Evandro D Bezerra, Madiha Iqbal, Javier Munoz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 6, 2022
Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study
Michael Wang, Javier Munoz, Andre Goy, et al.
Page
of 17